BackgroundDose optimization, such as dose reduction or dose spacing, is nowadays presented as a therapeutic strategy to be followed in patients with rheumatoid arthritis (RA) who have managed to reach and maintain clinical remission for a while. This strategy reduces the frequency of adverse effects and promotes cost savingsMethodsPatients with RA (Criteria ACR 1987) of the CREATE registry (patients who was treated in real life conditions) who had clinical remission (DAS28 <2.6) of at least 6 months of duration on November 1, 2013, constituted the cohort of patients who were optimized for the dose received. According to the consensus of the Spanish Societies of Rheumatology and Hospital Pharmacy, the optimization of doses meant the reduction of between 20 and 50% of the same.A multidisciplinary team of rheumatologists and clinical pharmacists in a third-level hospital was involved in decision-making on treatment and dose reduction, which involved the application of protocols and the follow-up of patients at least every two months.ResultsA prospective follow-up of 70 patients with RA who had received optimized doses of biological therapy for 3 years, with a mean age of 56.9 (13.7) years, of which 78.6% were women, 68.8% were positive rheumatoid factor and 66.7% ACPA +.The relapse occurred in 41.8% (at first year), 56.7% (at second year) and 62.7% (at third year). There were no statistical differences between these last 2 percentages. The median survival time of the optimization regimen was 15.24 (4.65) months (95% CI: 4.66–25.83). No statistically significant differences were found when comparing patients according to the optimized drug (antiTNF versus non-anti-TNF) (test log.rank: 0.239, p: 0.625).When relapse occurs, the patient returns to normal doses prior to optimization of the drug. Our data show that 62.7% of the patients in whom the relapse occurs at 3 years, maintains DAS28 <2,6 (P<0.05) when dose was returned to the manufacturer recommended dose.The 37.3% (95% CI: 26.72%, 49.28%) patients maintained the optimization pattern throughout the follow-up without relapse, with an average DAS28 of 1.99 (1.07) at 3 years. Comparing these patients with those who relapse, they achieved significantly lower DAS28 values at both (p: 0.028) and at three years (p: 0.025)Conclusions The strategy of dose reduction of biological therapies in patients with established RA that achieve sustained remission is possible in 37.3% of cases in real clinical practice (CREATE Registry) and it was maintained for 3 years.The probability of occurrence of relapse decreases after 2 years of treatment with an optimized regimen in those patients who have not relapsed before.This strategy is possible in patients with persistently controlled disease and in view of our results, it is independent of the drug administered (antiTNF versus non-antiTNF).After 3 years of follow-up, all patients maintained clinical remission (DAS 28 <2.6) despite relapses, and after resumption of the usual dose, all of them reached the therapeutic goal again.Patients ...
Background TNF antagonists have been successfully used for the treatment of rheumatoid arthritis (RA). However, data from clinical trials and databases have shown that patients treated with these biological agents have an increased risk of reactivation of latent tuberculosis (TB), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. The Spanish Society of Rheumatology (SSR) has made some recommendations. According to these guidelines it is mandatory to exclude tuberculosis infection with an evidence level (EL) 2b, Grade of evidence (GR) B. Serology for HBV (EL4, GRC) and HCV (EL4, GRC) are recommended as complementary tests. Purpose To establish the percentage of patients who underwent the recommended tests prior to treatment in a tertiary hospital. Latent infections are ruled out by a tuberculin test and chest x-rays (tuberculosis), HBV markers and HCV antibodies. Materials and methods Retrospective observational study of patients with RA who started treatment with biological agents between January 2010 and August 2011. Data were extracted from Farmatools and Sinapsis care databases. The variables collected were: age, sex, biological agent, BCG skin tests, chest x-rays, anti HCV antibodies and HBV markers. Results A total of 36 patients (78% female, 22% male), started a biological treatment for RA. The average age was 55 years. The drugs used were: etanercept 28%, adalimumab 69% and certolizumab 3%. Tuberculosis was evaluated in all patients, HCV in 58% and HBV in 56%. HCV and HBV tests were positive in 3% and 11% of the patients respectively. Conclusions Screening for tuberculosis infections is a common practice in this hospital. Serology for HCV and HBV were tested in a noteworthy percentage of patients although these complementary tests had recently been recommended by SSR. The pharmacy department may improve this goal by making a double check before the first dose is dispensed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.